Análise da Prevalência de Pacientes que Vivem com HIV Indetectáveis Pós-genotipagem Realizada por Falha Terapêutica Prévia

Letícia Silva; Felício de Freitas Netto; Fabiana  Postiglione Mansani; Thiago Martins Figueiredo; Eduardo Machado Dechandt

doi:10.36489/saudecoletiva.2024v14i92p14018-14027

Authors

Letícia Silva Universidade Estadual de Ponta Grossa
Felício de Freitas Netto Universidade Estadual de Ponta Grossa
Fabiana Postiglione Mansani Universidade Estadual de Ponta Grossa
Thiago Martins Figueiredo Universidade Estadual de Ponta Grossa
Eduardo Machado Dechandt Universidade Estadual de Ponta Grossa

DOI:

https://doi.org/10.36489/saudecoletiva.2024v14i92p14018-14027

Keywords:

HIV, Genotyping, Undetectable, Failure, Therapy

Abstract

Genotyping is na exam used to detects pecific mutations that generateres is tance to the antiretrovirals used in the standard treatment os patients living with the HIV virus (PVHIV), when a viral load great erthan 500 copies/m Lis confirmed after six months of correctad her enceto ART. Objective: evaluate the prevalence of patients living with undetectable HIV after genotyping performed due to previous virological failure. Method: this is a crosssectional study, with a quantitative approach, totaling 691 PLHIV records. Results and discussion: of theen tire sample analyzed (n=691), 160 patients had a formal indication of genotyping due to previous therapeutic failure, however,
only 69 under went it, of which 13 patients achieved undetectable load after the pharmacological change indicated by the test. The main indication for post-treatment genotyping in PLHIV is treatment failure. This, in turn, a rises – for themost part – from patients’ poor ther
apeuticad herence. The importance of genotyping in detectable PLHIV goes beyond the patientit self, buth as a notable epidemiological relevance, relating to non-transmissibility in undetectable patients.

References

UNAIDS. Programa Conjunto das Nações Unidas sobre HIV/AIDS (UNAIDS). Global AIDS UpDate. Disponível em:https://unaids.org.br/estatisticas/. Acesso em: 15 de setembro de 2023.

ASSEMBLEIA GERAL DA ONU. Declaração Política sobre HIV e AIDS : Acelerar a Resposta para lutar contra o HIV e acabar com a epidemia de AIDS até 2030. p. 24, 2016.

ADRIANO, AJGL. Programa Nacional de Doenças Sexualmente Transmissíveis/Síndrome da imunodeficiência adquirida. 2008.

BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos, 2018. Brasília, DF.

Adele SB, Gerson FMP, Lendel C, Amilcar T, André FS, Marcelo AS. Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil:Is it time for HIV cure in the country? BMC AIDS Research and Therapy. 2019;16 (1): 1–7.

Itezl GG, Jesús GG, Herzain LA, Benito PG, Eduardo VC, Maricarmen HDLR, et al. Calidad de vida y variables psicológicas que afectan la

adherencia al tratamiento anti-retroviral en pacientes mexicanos con infección por VIH/SIDA. RCI. 2019; 36 (3): 331–339.

BRASIL. Ministério da Saúde, Secretaria de Vigilância em Saúde. (2021). Boletim epidemiológico HIV/AIDS | 2021. Brasília, DF.

Claudia H, Nzovu U, Enju L, Said A, Ferdinand M, Guerino C, David S, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. JAC. 2016; 71 (7): 1966–1974.

Shimba H, Sello GM, Samuel EK, Jan MB, Seif A, Eric L, et al. Prevalence and patterns of HIV drug resistance in patients with suspected

virological failure in North-Western Tanzania. JAC. 2022; 77 (2): 483-491

Rami K, Allison DL, Leeann S, Marissa R, Emanuel K, Millicent O, et al. HIV-1 second-line failure and drug resistance at high-level and

low- level viremia in Western Kenya. Aids. 2018; 32 (17): 2485-2496.